Syros Pharmaceuticals Inc. (0LC7)
LSE 
Summary
0LC7 Chart
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default
Syros Pharmaceuticals Inc SYRS revealed on Tuesday that the SELECT-MDS-1 Phase 3 trial of tamibarotene did not meet its primary endpoint of complete response rate.
The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Syros Pharmaceuticals Inc. (0LC7) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Syros Pharmaceuticals Inc. ever had a stock split?
Syros Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | James E. Bradner CEO | LSE Exchange | US87184Q2066 ISIN |
| US Country | 68 Employees | - Last Dividend | 19 Sep 2022 Last Split | 30 Jun 2016 IPO Date |
Overview
Syros Pharmaceuticals, Inc. is a pioneering biopharmaceutical company engaged in developing novel treatments for hematologic malignancies, diseases affecting the blood and bone marrow. Originally known as LS22, Inc., the company underwent a name change to Syros Pharmaceuticals, Inc. in August 2012, marking a significant milestone in its commitment to healthcare innovation since its inception in 2011. Headquartered in the biotech hub of Cambridge, Massachusetts, Syros Pharmaceuticals leverages cutting-edge science to create transformative medicines for patients in dire need. The company's collaborative efforts with entities like Incyte Corporation for therapeutic target identification in myeloproliferative neoplasms and its licensing agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene underscore its strategic approach towards unlocking new treatment pathways.
Products and Services
Tamibarotene: Positioned as a leading candidate in Syros Pharmaceuticals' pipeline, Tamibarotene is a selective retinoic acid receptor alpha agonist. It is currently in Phase III clinical trial targeted at a genomically defined subset of patients with myelodysplastic syndrome. Additionally, it shows promise in a Phase II clinical trial for patients with acute myeloid leukemia. The development and commercialization rights for tamibarotene are part of a licensing agreement with TMRC Co. Ltd., showcasing its potential in addressing unmet medical needs within oncology.
SY-2101: Syros Pharmaceuticals is developing SY-2101 as a novel oral form of arsenic trioxide. This formulation is designed for the treatment of patients with acute promyelocytic leukemia, a subtype of acute myeloid leukemia characterized by abnormal accumulation of immature granulocytes. SY-2101 aims to improve treatment outcomes with a more convenient oral dosage form, potentially transforming the therapeutic experience for patients.
SY-5609: As part of Syros Pharmaceuticals’ innovative lineup, SY-5609 is a cyclin-dependent kinase 7 inhibitor undergoing a Phase I clinical trial. It is being explored for its efficacy in patients with select advanced solid tumors. SY-5609 represents the company’s commitment to expanding its oncology portfolio by exploring novel mechanisms of action against cancer.
